A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) (NCT07306832) — South Korea Trial Details

Condition(s) studied

Acute Myeloid Leukemia

Investigational drug(s) / intervention(s)

Pivekimab Sunirine: Intravenous

Study summary

Acute myeloid leukemia (AML) is an aggressive blood cancer, withwith few options for participants who relapse after treatment or who don't respond to treatment. This study will assess the adverse events and how pivekimab sunirine moves through the body in pediatric participants with relapsed or refractory (R/R) AML.

Pivekimab sunirine is a drug being evaluated in the treatment of AML. This is an open label, single arm study, participants will be enrolled in 1 of the 3 cohorts based on their age and will receive pivekimab sunirine at a dose based on their weight. Around 18 pediatric participants with a diagnosis of AML will be enrolled in the study at approximately 30 sites around the world.

Participants will receive intravenous (IV) pivekimab sunirine alone. The total study duration is approximately 28 months.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and checking for side effects.

Eligibility

Sex

ALL

Min age

6 Months

Max age

17 Years

Healthy volunteers

No

Inclusion Criteria: * Must have histologically confirmed acute myeloid leukemia (AML) meeting one of the following disease criteria: * Second or greater relapse. OR * Disease refractory to second or subsequent line of therapy (defined as resistant disease after at least one cycle of each treatment regimen). * Must have myeloid leukemic blasts that are CD123-positive by flow cytometry as determined by the treating institution. * Has \>= 5% myeloid leukemic blasts in bone marrow at time of relapse or refractory disease and prior to Screening for this study. * Performance status by Lansky (\< 16 years old at evaluation) or Karnofsky (\>= 16 years old at evaluation) score \>= 50 or ECOG score \<= 2. * May have status of central nervous system (CNS)1, CNS2, or CNS3 disease without clinical signs or neurologic symptoms suggestive of CNS leukemia, such as facial nerve palsy, brain/eye involvement or hypothalamic syndrome. Participants receiving intrathecal therapy and no additional CNS-directed systemic therapy at study entry are eligible and may continue treatment as clinically indicated in accordance with institutional practice. * For those participants who have not reached the age of consent, parent or legal guardian with the willingness and ability to provide informed consent and participant willing and able to give assent, as appropriate for age and country. Exclusion Criteria: * Known clinically significant cardiac disease. * Down syndrome. * Acute promyelocytic leukemia (APL) or juvenile myelomonocytic leukemia (JMML). * Symptomatic central nervous system (CNS3) disease * Prior history of any severity veno-occlusive disease/sinusoidal obstructive syndrome (VOD/SOS) of the liver. * Prior history of hematopoietic stem cell transplant within 6 months prior to Screening without evidence of active GvHD at the time of screening and the participant is off medications to treat or prevent either post-transplant graft-versus-host disease (GvHD) or post-transplant rejection (except for a stable dose of corticosteroids). * Have received prior Chimeric Antigen Receptor T-cell (CAR-T) therapy. * Any other known current malignancy requiring therapy. * Currently receiving anticancer therapy with antineoplastic intent, including radiotherapy, systemic therapy small molecules, monoclonal antibodies, other investigational agents, or high-dose chemotherapy with the exception of intrathecal therapy.

Primary outcome measure(s)

Number of Participants with Treatment-Emergent Adverse Events (TEAEs) Leading to Treatment Discontinuation — Up to Approximately 24 Months
Number of participants with protocol specified Treatment-Emergent Adverse Events (TEAEs) during and after treatment with pivekimab sunirine (PVEK). Severity of TEAEs will be graded according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0.
Maximum Observed Serum/Plasma Concentration (Cmax) of Intact Antibody-Drug Conjugate (ADC) — Up to Approximately 22 Months
Maximum observed serum/plasma concentration of intact ADC.
Cmax of FGN849 Payload — Up to Approximately 22 Months
Maximum observed serum/plasma concentration of FGN849 payload.
Area Under the Concentration-Time Curve (AUC) of Intact ADC — Up to Approximately 22 Months
Area under the concentration-time curve of intact ADC.
AUC of FGN849 payload — Up to Approximately 22 Months
Area under the concentration-time curve of FGN849 payload.
Time to Cmax (Tmax) of Intact ADC — Up to Approximately 22 Months
Time to Cmax of intact ADC.
Tmax of FGN849 Payload — Up to Approximately 22 Months
Time to Cmax of payload.

Trial sites (14)

Facility	City	Region	Status
Lucile Packard Children's Hospital /ID# 276015	Palo Alto	California	Recruiting
Children'S Healthcare Of Atlanta - Arthur M. Blank Hospital /ID# 275740	Atlanta	Georgia	Recruiting
New York Medical College /ID# 275597	Valhalla	New York	Recruiting
Tristar Centennial Medical Center /ID# 275831	Nashville	Tennessee	Recruiting
Children's Medical Center Dallas /ID# 275930	Dallas	Texas	Recruiting
The Children's Hospital at Westmead /ID# 275672	Westmead	New South Wales	Recruiting
Perth Children'S Hospital /ID# 275673	Perth	Western Australia	Recruiting
Chu Bordeaux - Hopital Pellegrin /ID# 277645	Bordeaux	New Aquitaine	Recruiting
Hopital Armand Trousseau /ID# 276231	Paris	France	Recruiting
Ospedale Pediatrico Bambino Gesu /ID# 275692	Rome	Roma	Recruiting
Seoul National University Hospital /ID# 276978	Seoul	Seoul Teugbyeolsi	Recruiting
Samsung Medical Center /ID# 276979	Seoul	Seoul Teugbyeolsi	Recruiting
National Taiwan University Hospital /ID# 276635	Taipei	Taiwan	Recruiting
Cambridge University Hospital /ID# 277041	Cambridge	Cambridgeshire	Recruiting

More AbbVie trials in South Korea

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer Recruiting

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 Recruiting

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) Active, not recruiting

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Recruiting

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan Recruiting

Other trials for the same condition

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Recruiting

A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid Leukemia Recruiting

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Active, not recruiting

A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid Leukemia Recruiting

CINC424A2X01B Rollover Protocol Active, not recruiting